Insight

Maria Babak: Vimseltinib in treating TGCT is definitely one to watch

Photo from Maria (Masha) Babak/LinkedIn

Oct 3, 2024, 17:50

Maria Babak: Vimseltinib in treating TGCT is definitely one to watch

Maria Babak shared a post on LinkedIn by The Babak Lab, about a recent paper by Hans Gelderblom et al. published in Clinical Cancer Research.

“CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib”

Authors: Hans Gelderblom, Albiruni Razak, Rodrigo Ruiz-Soto, Matthew Sherman, William Tap et al.

“Vimseltinib in treating TGCT is definitely one to watch! With a 72% response rate and a well-tolerated safety profile, it offers new hope for patients who aren’t candidates for surgery. It’s exciting to see targeted therapies making such an impact in oncology”

Quoting

“Exciting Advances in Cancer Treatment!

A recent clinical trial of vimseltinib, a new tyrosine kinase inhibitor, has shown promising results in treating tenosynovial giant cell tumor (TGCT) – particularly in patients where surgery isn’t an option.

Key Results:

72% response rate in patients with TGCT.
Well-tolerated with manageable side effects.
Long-lasting responses, with patients on treatment for over 2 years.
With limited options for those not eligible for surgery, vimseltinib represents a breakthrough in TGCT treatment.

More research is on the horizon, but these findings highlight the potential for targeted therapies in oncology!”

Maria Babak: Vimseltinib in treating TGCT is definitely one to watch

Sources: Maria Babak/LinkedIn and

More posts featuring Maria Babak on oncodaily.com

Maria (Masha) Babak is the Head of The Babak Lab and an Assistant Professor at the City University of Hong Kong. In November 2020, she joined the City University of Hong Kong as an assistant professor. Dr. Babak received the Graeme Hanson-AsBIC Early Career Award in 2022.

Her research interests are at the intersection of chemistry, biology, and medicine, with a focus on the discovery and preclinical development of anticancer drugs for resistant and aggressive cancers with limited treatment options, such as malignant pleural mesothelioma and brain metastases.